- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Glenmark Pharmaceuticals' Board has proposed a final dividend of Rs. 2.50 per equity share for the financial year 2025-26. This equates to a 250% payout on the Re. 1 face value per share. For shareholders, this signifies a direct cash return, contingent on their formal approval at the company's upcoming Annual General Meeting. This proposed dividend highlights the company's focus on distributing value back to investors. Shareholders should monitor for the AGM outcome regarding this payout.